83101-13-7

Upstream product

• 170859-72-0 3-(3-hydroxyprop-1-yn-1-yl)benzonitrile 
• 69113-59-3 3-iodobenzonitrile 
• 42287-97-8 3-(3-cyanophenyl)propanoic acid 
• 98116-50-8 3-(3-cyanophenyl)-2-(E)-propen-1-ol 
• 1504-64-9 3-(3-nitrophenyl)prop-2-en-1-ol 
• 1504-76-3 3-nitrocinnamaldehyde 
• 6952-59-6 3-cyanobromobenzene 
• 61463-62-5 3-allyl benzonitrile 

Downstream Products

• 83101-15-9 3-(3-bromopropyl)cyanobenzene 
• 111376-39-7 3-(3-oxopropyl)benzonitrile 
• 83101-80-8 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-76-2 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-92-2 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-benzamidine; hydriodide 
• 83116-31-8 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-benzamidine; hydriodide 
• 83101-71-7 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-72-8 3-[4-Phenylcarbamoyl-4-(toluene-4-sulfonylamino)-butyl]-thiobenzimidic acid methyl ester; hydriodide 
• 83101-85-3 5-(3-Carbamimidoyl-phenyl)-2-(toluene-4-sulfonylamino)-pentanoic acid phenylamide; hydriodide 
• 83101-84-2 3-[5-Morpholin-4-yl-5-oxo-4-(toluene-4-sulfonylamino)-pentyl]-benzamidine; hydriodide 
• 83101-67-1 3-[5-Morpholin-4-yl-4-(naphthalene-2-sulfonylamino)-5-oxo-pentyl]-thiobenzamide 
• 83101-63-7 3-[5-Morpholin-4-yl-4-(naphthalene-1-sulfonylamino)-5-oxo-pentyl]-thiobenzamide 
• 83101-54-6 5-(3-Cyanphenyl)-2-β-naphthylsulfonylaminovaleriansaeuremorpholid 
• 83101-50-2 5-(3-Cyanphenyl)-2-α-naphthylsulfonylaminovaleriansaeuremorpholid 

Relevant academic research and scientific papers

Cobalt-catalyzed (Z)-selective semihydrogenation of alkynes with molecular hydrogen

Cobalt-catalyzed highly (Z)-selective semihydrogenation of alkynes using molecular H2 was developed using commercially available and cheap cobalt precursors. A variety of (Z)-alkenes were obtained in moderate to excellent selectivities [(Z)-alkene/(E)-alkene/alkane ratio up to >99 : 1 : 1] and it was found that the readily available ethylenediamine ligand is crucial in determining the selectivity.

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

PHENETANOLAMINE DERIVATIVES

Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example asthma or chronic o

1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol

Methods and devices for the diagnosis, evaluation and treatment of coronary artery disease (CAD) by means of a closed-loop drug delivery system that delivers an exercise simulating agent, including novel exercise simulating agents which elicit both acute

Organic compounds and their pharmaceutical use

There are provided anti-allergic pharmaceutical compounds of formula: STR1 in which n is 0, 1 or 2; R1 is a hydrocarbyl group containing 6 to 30 carbon atoms and optionally substituted with an optionally substituted phenyl group; R2